WO1998006704A1 - Arylalkanoylpyridazine - Google Patents
Arylalkanoylpyridazine Download PDFInfo
- Publication number
- WO1998006704A1 WO1998006704A1 PCT/EP1997/004191 EP9704191W WO9806704A1 WO 1998006704 A1 WO1998006704 A1 WO 1998006704A1 EP 9704191 W EP9704191 W EP 9704191W WO 9806704 A1 WO9806704 A1 WO 9806704A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- benzoyl
- formula
- pyridazine
- tetrahydro
- methoxyphenyl
- Prior art date
Links
- 0 B*N*1C=CC(*C(N(CCC2)N=C2c2cc(*)c(*)cc2)=O)=CC=C1 Chemical compound B*N*1C=CC(*C(N(CCC2)N=C2c2cc(*)c(*)cc2)=O)=CC=C1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the invention relates to arylalkanoylpyridazine derivatives of the formula I.
- Q is absent or alkylene with 1 -6 C atoms
- R ⁇ R 2 each independently of one another -OH, OR 5 , -SR 5 ,
- R 1 and R 2 together also -O-CH 2 -O-,
- R 5 and R 6 are each independently A, cycloalkyl with 3-7
- A each independently of one another alkyl having 1 to 10 carbon atoms, which can be substituted by 1 to 5 F and / or Cl atoms and
- 1-Benzoyl tetrahydropyridazines as progesterone receptor ligands are e.g. in J. Med.Chem. 38, 4878 (1995).
- the invention was based on the task of finding new compounds with valuable properties, in particular those which can be used for the production of medicaments.
- the anti-asthmatic effect can e.g. B. by the method of T. Olsson, Acta allergologica 26, 438-447 (1971).
- the compounds also have an inhibitory effect on the formation of TNF (tumor necrosis factor) and are therefore suitable for the treatment of allergic and inflammatory diseases, autoimmune diseases and graft rejection reactions. They can also be used to treat memory disorders.
- TNF tumor necrosis factor
- the compounds of formula I can be used as active pharmaceutical ingredients in the
- the invention accordingly relates to the compounds of the formula I and a process for the preparation of compounds of the formula I according to claim 1 and their salts, characterized in that a compound of the formula II
- R 1 and R 2 have the meanings given
- L is Cl, Br, OH or a reactive esterified OH group
- radicals R 1 , R 2 , B, Q and L have the meanings given in the formulas I, II, III, IV and V, unless expressly stated otherwise.
- a and A ' is preferably alkyl, more preferably alkyl substituted by 1 to 5 fluorine and / or chlorine atoms.
- alkyl is preferably unbranched and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, preferably 1, 2, 3, 4 or 5 carbon atoms and is preferably methyl , Ethyl, trifluoromethyl, pentafluoroethyl or propyl, further preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl or isopentyl.
- Cycloalkyl preferably has 3-7 C atoms and is preferably cyclopropyl and cyclobutyl, further preferably cyclopentyl or cyclohexyl, and also cycloheptyl.
- Methylene cycloalkyl preferably has 4-8 C atoms and preferably stands for methylene cyclopropyl and methylene cyclobutyl, further preferably for thylencyclopentyl and methylene cyclohexyl, also for methylene cycloheptyl.
- Alkenyl is preferably vinyl, 1- or 2-propenyl, 1-butenyl, isobutenyl, sec-butenyl, further preferred is 1-pentenyl, isopentyl or 1-hexenyl.
- Alkylene is preferably unbranched and is preferably methylene or ethylene, more preferably propylene or butylene.
- R 1 and R 2 can be the same or different and are in the 3- or 4-position of the phenyl ring. They mean, for example, independently of one another hydroxy, -S-CH 3 , -SO-CH 3 , -SO - CH3, F, Cl, Br or
- I or together methylenedioxy are particularly preferably each methoxy, ethoxy, propoxy, cyclopentoxy, or else fluorine, difluoro, trifluoromethoxy, 1-fluorine, 2-fluorine, 1,2-difluoro, 2,2-difluoro, 1, 2,2-trifluoro or 2,2,2-trifluoroethoxy.
- the radical B is preferably 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, further preferably 1,2,3-triazol-1-, -4- or -5-yl, 1, 2,4-triazol- 1-, -3- or
- the radical B is preferably also methyl, ethyl, propyl, n-butyl, methoxy, ethoxy, propoxy, N-methylamino, N, N-dimethylamino, N-ethylamino or N, N-diethylamino.
- the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.
- Some preferred groups of compounds can be expressed by the following partial formulas Ia to Id, which correspond to the formula I and in which the radicals which are not specified in more detail than those in the formula
- B is pyridinyl, pyrazinyl, pyrimidinyl, thiazolyl, imidazolyl or isoxazolyl;
- R 1 and R 2 each independently represent OA, Q methylene and B pyridinyl, pyrazinyl, pyrimidinyl, thiazolyl.lmidazolyl or isoxazolyl;
- OA, Q are absent and BA or OA mean.
- R 1 , R 2 and Q have the meanings indicated, in particular the preferred meanings indicated.
- Q is preferably methylene or ethylene, more preferably propylene or butylene.
- B has the preferred meanings indicated in the compounds of the formulas III and V, while L denotes Cl, Br, OH or a reactive esterified OH group.
- L is a reactive esterified OH group, this is preferably alkylsulfonyloxy with 1 -6 C atoms (preferably methylsulfonyloxy) or arylsulfonyloxy with 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy, also 2- Naphthalenesulfonyloxy).
- the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
- the reaction it is possible to carry out the reaction in stages.
- the compounds of the formula I can preferably be obtained by reacting compounds of the formula II with compounds of the formula III.
- the compounds of the formula II are reacted with the compounds of the formula III in the presence or absence of an inert solvent at temperatures between about -20 and about 150 °, preferably between 20 and 100 °.
- Suitable inert solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as
- Trichlorethylene 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane
- Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol
- Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane
- Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone
- Amides such as acetamide, dimethylacetamide or dimethylformamide (DMF); Nitriles such as acetonitrile
- Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulfide
- Carboxylic acids such as formic acid or ace
- Compounds of the formula I can furthermore be obtained by reacting compounds of the formula IV with compounds of the formula V.
- the starting compounds of the formulas IV and V are generally known. If they are not known, they can be produced by methods known per se.
- the radical -CO-L is a preactivated carboxylic acid, preferably a carboxylic acid halide.
- reaction of the compounds of the formula IV with compounds of the formula V takes place under the same conditions, with regard to the reaction time, temperature and solvent, as is described for the reaction of the compounds of the formula II with compounds of the formula III.
- a base of the formula I can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and subsequent evaporation.
- acids that provide physiologically acceptable salts are suitable for this implementation.
- So inorganic acids can be used, e.g. Sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, also organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g.
- Formic acid acetic acid, propionic acid, pivalic acid, diethyl acetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methanoic acid, ethanesulfonic acid, ethanesulfonic acid, ethanesulfonic acid, ethanesulfonic acid, , Benzenesulfonic acid, p-toluenesulfonic acid, naphthalene mono- and disutfonic acids, laurylsulfuric acid. Salts with physiologically unacceptable acids, e.g. Picrates can be used for the isolation and / or purification of the compounds of the formula I.
- Salts with physiologically unacceptable acids e.g. Picrates can be used for the isolation and / or
- the free bases of formula I can be liberated from their salts with bases (e.g. sodium or potassium hydroxide or carbonate).
- the invention furthermore relates to the use of the compounds of the formula I and / or their physiologically acceptable salts for the preparation of provision of pharmaceutical preparations, in particular by non-chemical means. They can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active ingredients.
- the invention also relates to medicaments of the formula I and their physiologically acceptable salts as phosphodiesterase IV inhibitors.
- the invention further relates to pharmaceutical preparations containing at least one compound of the formula I and / or one of its physiologically acceptable salts.
- Suitable carrier substances are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin , Carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly.
- Tablets, pills, dragees, capsules, powders, granules, syrups, juices or drops are used in particular for oral use, suppositories for rectal use, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for which topical application ointments, creams or
- the new compounds can also be lyophilized and the resulting lyophilisates e.g. can be used for the production of injectables.
- the specified preparations can be sterilized and / or auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure,
- Contain buffer substances Contain buffer substances, coloring, flavoring and / or several other active ingredients, e.g. one or more vitamins.
- the compounds of the formula I and their physiologically acceptable salts can be used in combating diseases in which an increase in the cAMP (cyclo-adenosine monophosphate) level leads to inflammation. inhibition or prevention and muscle relaxation.
- the compounds according to the invention can be used particularly in the treatment of allergies, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases and autoimmune diseases.
- customary work-up means: if necessary, water is added and, if necessary, the pH is adjusted to between 2 and 10, depending on the constitution of the end product, extracted with
- a suspension of 4.70 g of 3- (3,4-dimethoxyphenyl) -1, 4,5,6-tetrahydropyridazine ("A") in 150 ml of THF is mixed with 2.24 g of potassium tert-butoxide and stirred for 30 minutes.
- 7.3 g of 4-nicotinoylaminobenzoyl chloride are added and the mixture is subsequently stirred at room temperature for 10 hours. The solvent is removed and worked up as usual.
- Example A Injection glasses
- a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection glass contains 5 mg of active ingredient.
- Example B Suppositories
- a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and left to cool. Each suppository contains 20 mg of active ingredient.
- a solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH 2 PO 4 .2H 2 O, 28.48 g of Na 2 HPO 4 .12H 2 O and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 I and sterilized by irradiation. This solution can be used in the form of eye drops.
- Example D ointment
- 500 mg of an active ingredient of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
- a mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient.
- Example F coated tablets
- Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
- Example G capsules
- a solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.
- Example i Inhalation spray
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0001760A HUP0001760A3 (en) | 1996-08-13 | 1997-08-01 | Arylacyl pyridazine derivatives, pharmaceutical compositions containing them, process for producing them and use of the compounds for producing pharmaceutical compositions |
CA002263417A CA2263417C (en) | 1996-08-13 | 1997-08-01 | Arylalkanoylpyridazines |
US09/230,801 US6107295A (en) | 1997-08-01 | 1997-08-01 | Arylalkanoyl pyridazines |
AU40133/97A AU725652B2 (en) | 1996-08-13 | 1997-08-01 | Arylalkanoylpyridazines |
SK168-99A SK282480B6 (sk) | 1996-08-13 | 1997-08-01 | Derivát arylalkanoylpyridazínu, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje |
DE59711450T DE59711450D1 (en) | 1996-08-13 | 1997-08-01 | Arylalkanoylpyridazine |
JP1998509348A JP4198755B6 (ja) | 1996-08-13 | 1997-08-01 | アリールアルカノイルピリダジン誘導体 |
DK97937540T DK0922036T3 (da) | 1996-08-13 | 1997-08-01 | Arylalkanoylpyridaziner |
EP97937540A EP0922036B1 (de) | 1996-08-13 | 1997-08-01 | Arylalkanoylpyridazine |
SI9730631T SI0922036T1 (en) | 1996-08-13 | 1997-08-01 | Arylalkanoyl pyridazines |
BR9711066A BR9711066A (pt) | 1996-08-13 | 1997-08-01 | Arilacanoilpiridazinas |
AT97937540T ATE262512T1 (de) | 1996-08-13 | 1997-08-01 | Arylalkanoylpyridazine |
NO19990676A NO312295B1 (no) | 1996-08-13 | 1999-02-12 | Arylalkanoylpyridaziner, fremgangsmåte for fremstilling derav, farmasöytiske preparater, fremgangsmåte for fremstillingderav, samt anvendelse av forbindelsene til fremstilling avpreparatene |
HK00100584A HK1021732A1 (en) | 1996-08-13 | 2000-01-31 | Arylalkanoyl pyridazine derivatives and preparing thereof, pharmaceutical containing the same and their use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19632549.8 | 1996-08-13 | ||
DE19632549A DE19632549A1 (de) | 1996-08-13 | 1996-08-13 | Arylalkanoylpyridazine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/525,455 Division US6479494B1 (en) | 1996-08-13 | 2000-03-15 | Arylalkanoyl pyridazines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998006704A1 true WO1998006704A1 (de) | 1998-02-19 |
Family
ID=7802479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/004191 WO1998006704A1 (de) | 1996-08-13 | 1997-08-01 | Arylalkanoylpyridazine |
Country Status (24)
Country | Link |
---|---|
US (1) | US6479494B1 (de) |
EP (1) | EP0922036B1 (de) |
KR (1) | KR100554876B1 (de) |
CN (1) | CN1109022C (de) |
AR (1) | AR009069A1 (de) |
AT (1) | ATE262512T1 (de) |
AU (1) | AU725652B2 (de) |
BR (1) | BR9711066A (de) |
CA (1) | CA2263417C (de) |
CZ (1) | CZ291851B6 (de) |
DE (2) | DE19632549A1 (de) |
DK (1) | DK0922036T3 (de) |
ES (1) | ES2214633T3 (de) |
HK (1) | HK1021732A1 (de) |
HU (1) | HUP0001760A3 (de) |
NO (1) | NO312295B1 (de) |
PL (1) | PL331557A1 (de) |
PT (1) | PT922036E (de) |
RU (1) | RU2201923C2 (de) |
SI (1) | SI0922036T1 (de) |
SK (1) | SK282480B6 (de) |
TW (1) | TW427980B (de) |
WO (1) | WO1998006704A1 (de) |
ZA (1) | ZA977206B (de) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026201A1 (de) * | 1998-11-04 | 2000-05-11 | Merck Patent Gmbh | Benzoylpyridazine |
WO2000059890A1 (de) * | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Tetrahydropyridazin-derivate |
WO2000059484A2 (de) * | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Verwendung von arylalkanoylpyridazinen |
WO2003037349A1 (en) * | 2001-10-31 | 2003-05-08 | Merck Patent Gmbh | Type 4 phosphodiesterase inhibitors and uses thereof |
WO2003039548A1 (en) * | 2001-11-05 | 2003-05-15 | Merck Patent Gmbh | Hydrazono-malonitriles |
WO2003104204A1 (de) * | 2002-06-05 | 2003-12-18 | Merck Patent Gmbh | Pyridazinderivate |
WO2003104205A1 (de) * | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
WO2004000839A1 (de) * | 2002-06-19 | 2003-12-31 | Merck Patent Gmbh | Thiazolderivate als phosphodiesterase iv-inhibtoren |
US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
JP2004519450A (ja) * | 2000-12-23 | 2004-07-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ベンゾイルピリダジン |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
KR100673638B1 (ko) * | 1998-06-16 | 2007-01-23 | 메르크 파텐트 게엠베하 | 아릴 알카노일피리다진류 |
EP2193808A1 (de) | 1999-08-21 | 2010-06-09 | Nycomed GmbH | Synergistische Kombination |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
EP2258357A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
EP2275095A2 (de) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
WO2011063115A1 (en) | 2009-11-19 | 2011-05-26 | Braincells Inc. | Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis |
US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
WO2011091033A1 (en) | 2010-01-20 | 2011-07-28 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19932315A1 (de) | 1999-07-10 | 2001-01-11 | Merck Patent Gmbh | Benzoylpyridazine |
CN1235589C (zh) * | 2001-02-12 | 2006-01-11 | 默克专利股份公司 | 4型磷酸二酯酶抑制剂在制备治疗心肌疾病药物中的应用 |
MY153720A (en) | 2005-11-15 | 2015-03-13 | Otsuka Pharma Co Ltd | Oxazole compound and pharmaceutical composition |
WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001412A1 (en) * | 1992-07-01 | 1994-01-20 | Ortho Pharmaceutical Corporation | 1-arylsulphonyl, arylcarbonyl and 1-arylphosphonyl-3-phenyl-1,4,5,6-tetrahydropyridazines |
-
1996
- 1996-08-13 DE DE19632549A patent/DE19632549A1/de not_active Withdrawn
-
1997
- 1997-08-01 DE DE59711450T patent/DE59711450D1/de not_active Expired - Lifetime
- 1997-08-01 DK DK97937540T patent/DK0922036T3/da active
- 1997-08-01 AU AU40133/97A patent/AU725652B2/en not_active Ceased
- 1997-08-01 WO PCT/EP1997/004191 patent/WO1998006704A1/de not_active Application Discontinuation
- 1997-08-01 CN CN97197181A patent/CN1109022C/zh not_active Expired - Fee Related
- 1997-08-01 HU HU0001760A patent/HUP0001760A3/hu unknown
- 1997-08-01 BR BR9711066A patent/BR9711066A/pt not_active IP Right Cessation
- 1997-08-01 EP EP97937540A patent/EP0922036B1/de not_active Expired - Lifetime
- 1997-08-01 SK SK168-99A patent/SK282480B6/sk not_active IP Right Cessation
- 1997-08-01 CA CA002263417A patent/CA2263417C/en not_active Expired - Fee Related
- 1997-08-01 ES ES97937540T patent/ES2214633T3/es not_active Expired - Lifetime
- 1997-08-01 PL PL97331557A patent/PL331557A1/xx unknown
- 1997-08-01 CZ CZ1999493A patent/CZ291851B6/cs not_active IP Right Cessation
- 1997-08-01 KR KR1019997001132A patent/KR100554876B1/ko not_active IP Right Cessation
- 1997-08-01 SI SI9730631T patent/SI0922036T1/xx unknown
- 1997-08-01 AT AT97937540T patent/ATE262512T1/de not_active IP Right Cessation
- 1997-08-01 PT PT97937540T patent/PT922036E/pt unknown
- 1997-08-01 RU RU99105211/04A patent/RU2201923C2/ru not_active IP Right Cessation
- 1997-08-11 TW TW086111479A patent/TW427980B/zh active
- 1997-08-12 ZA ZA9707206A patent/ZA977206B/xx unknown
- 1997-08-13 AR ARP970103679A patent/AR009069A1/es not_active Application Discontinuation
-
1999
- 1999-02-12 NO NO19990676A patent/NO312295B1/no not_active IP Right Cessation
-
2000
- 2000-01-31 HK HK00100584A patent/HK1021732A1/xx not_active IP Right Cessation
- 2000-03-15 US US09/525,455 patent/US6479494B1/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001412A1 (en) * | 1992-07-01 | 1994-01-20 | Ortho Pharmaceutical Corporation | 1-arylsulphonyl, arylcarbonyl and 1-arylphosphonyl-3-phenyl-1,4,5,6-tetrahydropyridazines |
Non-Patent Citations (1)
Title |
---|
D. COMBS: "NONSTEROIDAL PROGESTERONE RECEPTOR LIGANDS.1.3-ARYL-1-BENZOYL-TETRAHYDROPYRIDAZINES.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 38, no. 25, 1995, WASHINGTON US, pages 4878 - 4879, XP002047380 * |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100673638B1 (ko) * | 1998-06-16 | 2007-01-23 | 메르크 파텐트 게엠베하 | 아릴 알카노일피리다진류 |
US6376493B1 (en) | 1998-11-04 | 2002-04-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Benzoylpyridazines |
AU759328B2 (en) * | 1998-11-04 | 2003-04-10 | Merck Patent Gmbh | Benzoylpyridazines |
WO2000026201A1 (de) * | 1998-11-04 | 2000-05-11 | Merck Patent Gmbh | Benzoylpyridazine |
WO2000059890A1 (de) * | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Tetrahydropyridazin-derivate |
WO2000059484A2 (de) * | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Verwendung von arylalkanoylpyridazinen |
WO2000059484A3 (de) * | 1999-04-06 | 2001-08-23 | Merck Patent Gmbh | Verwendung von arylalkanoylpyridazinen |
EP2193808A1 (de) | 1999-08-21 | 2010-06-09 | Nycomed GmbH | Synergistische Kombination |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
US7189515B2 (en) | 1999-12-06 | 2007-03-13 | Biosite, Inc. | Human antibodies as detection reagents |
US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
JP2004519450A (ja) * | 2000-12-23 | 2004-07-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ベンゾイルピリダジン |
WO2003037349A1 (en) * | 2001-10-31 | 2003-05-08 | Merck Patent Gmbh | Type 4 phosphodiesterase inhibitors and uses thereof |
WO2003039548A1 (en) * | 2001-11-05 | 2003-05-15 | Merck Patent Gmbh | Hydrazono-malonitriles |
US7544684B2 (en) | 2001-11-05 | 2009-06-09 | Merck Patent Gmbh | Hydrazono-malonitriles |
US7141572B2 (en) | 2001-11-05 | 2006-11-28 | Merck Patent Gesellschaft | Hydrazono-malonitriles |
US7563790B2 (en) | 2002-06-05 | 2009-07-21 | Merck Patent Gmbh | Pyridazine derivatives |
JP2005534660A (ja) * | 2002-06-05 | 2005-11-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ピリダジン誘導体 |
US7129241B2 (en) | 2002-06-05 | 2006-10-31 | Merck Patent Gesellschaft | Pyridazine derivatives |
AU2003227746B2 (en) * | 2002-06-05 | 2009-03-19 | Merck Patent Gmbh | Pyridazine derivatives |
WO2003104204A1 (de) * | 2002-06-05 | 2003-12-18 | Merck Patent Gmbh | Pyridazinderivate |
WO2003104205A1 (de) * | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
US7135471B2 (en) | 2002-06-10 | 2006-11-14 | Merck Patent Gmbh | Aryl oximes |
JP2005533050A (ja) * | 2002-06-10 | 2005-11-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | アリールオキシム |
US7470687B2 (en) | 2002-06-10 | 2008-12-30 | Merck Patent Gmbh | Aryl oximes |
US7790723B2 (en) | 2002-06-19 | 2010-09-07 | Merck Patent Gmbh | Thiazole derivatives as phosphodiesterase IV inhibitors |
AU2003232215B2 (en) * | 2002-06-19 | 2009-04-30 | Merck Patent Gmbh | Thiazole derivatives as phosphodiesterase IV inhibitors |
JP2005530825A (ja) * | 2002-06-19 | 2005-10-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | チアゾール誘導体 |
WO2004000839A1 (de) * | 2002-06-19 | 2003-12-31 | Merck Patent Gmbh | Thiazolderivate als phosphodiesterase iv-inhibtoren |
EP2258359A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
EP2275096A2 (de) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
EP2258358A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
EP2258357A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
EP2275095A2 (de) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
EP2377530A2 (de) | 2005-10-21 | 2011-10-19 | Braincells, Inc. | Modulation von Neurogenese durch PDE-Hemmung |
US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
EP2382975A2 (de) | 2006-05-09 | 2011-11-02 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
WO2011063115A1 (en) | 2009-11-19 | 2011-05-26 | Braincells Inc. | Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis |
WO2011091033A1 (en) | 2010-01-20 | 2011-07-28 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0922036B1 (de) | Arylalkanoylpyridazine | |
EP0763534B1 (de) | Arylalkyl-diazinone als Phosphodiesterase IV-Hemmer | |
EP0934301A1 (de) | Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren | |
EP1087946B1 (de) | Arylalkanoylpyridazine | |
EP0738715B1 (de) | Arylalkyl-pyridazinone | |
EP1226143B1 (de) | Imidazopyridinderivate als phosphodiesterase vii-hemmer | |
EP1215210A2 (de) | Benzufurane | |
EP1124809B1 (de) | Benzoylpyridazine | |
EP0863898A1 (de) | Endothelin-rezeptor-antagonisten | |
DE19604388A1 (de) | Arylalkyl-diazinone | |
WO2000059890A1 (de) | Tetrahydropyridazin-derivate | |
EP0618201A1 (de) | Thiadiazinone und ihre verwendung zur Bekämpfung von Cardiovaskulären sowie asthmatischen erkrankkungen | |
EP1143944A3 (de) | Verwendung von arylalkanoylpyridazinen | |
DE10064997A1 (de) | Benzoylpyridazine | |
EP1194411B1 (de) | Benzoylpyridazine | |
EP1406878A1 (de) | 4-(benzyliden-amino)-3-(methylsulfanyl) -4h-(1, 2, 4) triazin-5-on derivate mit pde -iv hemmender und tnf-antagonistischer wirkung zur behandlung von herzkrankheiten und allergien | |
WO1998027091A1 (de) | Endothelin-rezeptor-antagonisten als pestizide | |
WO2003008373A1 (de) | Tyrosinhydrazide | |
DE10135009A1 (de) | Triazinderivate | |
DE10156229A1 (de) | Triazinderivate | |
DE10156230A1 (de) | Tyrosinhydrazide | |
EP0647627A1 (de) | 1,2-Dihydro-2-oxo-3-Methylsulfonylaminomethyl-Pyridine als Angiotensin II Antagonisten | |
DE10135248A1 (de) | Tyrosinhydrazide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97197181.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997937540 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09230801 Country of ref document: US Ref document number: PA/a/1999/001386 Country of ref document: MX Ref document number: 16899 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2263417 Country of ref document: CA Ref document number: 2263417 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997001132 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 1998 509348 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-493 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-493 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1997937540 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997001132 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1999-493 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997937540 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997001132 Country of ref document: KR |